Head-to-head · WeighScore
Blis MD vs FlyteHealth
The verdict
Blis MD takes it — 72.5/100 to 58.6/100.
Blis MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Blis MD is a US telehealth offering personalized GLP-1 weight-loss treatment with compounded semaglutide and tirzepatide, prescribed after a free virtual consultation with a licensed provider.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Blis MD | FlyteHealth |
|---|---|---|
| WeighScore | 72.5/100 | 58.6/100 |
| Grade | C | C |
| Scorecard rank | #76 | #363 |
| Semaglutide | $139/mo | Not disclosed |
| Tirzepatide | $199/mo | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #76 · C
Strengths
- Transparent flat monthly pricing published upfront (139 dollars semaglutide, 199 dollars tirzepatide)
- Free initial virtual consultation with a licensed provider
- Both semaglutide and tirzepatide offered with ongoing provider check-ins
Where it loses points
- Compounding pharmacy is not named publicly
- States served are not listed on the site
- Thin public trust signals (no LegitScript seal or named medical director found)
Graded #363 · C
Strengths
- Care led by board-certified obesity-medicine physicians
- Multidisciplinary team with NPs, dietitians, and care coordinators
- Published outcomes of about 13 to 16 percent weight loss over 12 months
- High GLP-1 medication adherence (around 86 percent in reported data)
- Comprehensive cardiometabolic care beyond GLP-1 alone
Where it loses points
- Distributed primarily via employers, payers, and health plans, not direct cash-pay
- Access is largely gated behind employer or plan sponsorship
- GLP-1 is prescribed only when appropriate, not guaranteed
- Self-pay pricing is not publicly listed (contact required)
- Less suited to consumers wanting fast direct-to-door GLP-1
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.